Gainers

  • iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 32.0% to $0.41 during Friday's after-market session. The company's market cap stands at $4.9 million.
  • Quanterix (NASDAQ:QTRX) shares increased by 8.88% to $2.82. The company's market cap stands at $135.2 million. As per the news, the Q2 earnings report came out 4 days ago.
  • Obsidian Therapeutics (NASDAQ:OBX) shares increased by 6.92% to $19.0. The market value of their outstanding shares is at $1.1 billion.
  • AEON Biopharma (AMEX:AEON) shares moved upwards by 5.34% to $0.29. The company's market cap stands at $11.9 million. As per the news, the Q2 earnings report came out 2 days ago.
  • TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 5.18% to $3.45. The market value of their outstanding shares is at $3.6 million.
  • Milestone Scientific (AMEX:MLSS) shares rose 4.86% to $0.52. The company's market cap stands at $48.7 million. As per the news, the Q2 earnings report came out yesterday.

Losers

  • Streamex (NASDAQ:STEX) shares decreased by 11.5% to $0.92 during Friday's after-market session. The market value of their outstanding shares is at $90.2 million. As per the news, the Q2 earnings report came out today.
  • Ensysce Biosciences (NASDAQ:ENSC) stock fell 11.28% to $0.35. The market value of their outstanding shares is at $5.3 million. As per the press release, Q2 earnings came out yesterday.
  • Cue Biopharma (NASDAQ:CUE) stock decreased by 9.27% to $31.03. The company's market cap stands at $130.5 million. As per the press release, Q2 earnings came out today.
  • Cerenome (NASDAQ:CNSY) shares fell 8.55% to $3.37. The market value of their outstanding shares is at $25.4 million.
  • ENvue Medical (NASDAQ:FEED) shares fell 8.47% to $0.4. The company's market cap stands at $3.5 million.
  • 60 Degrees (NASDAQ:SXTP) shares declined by 6.97% to $1.11. The market value of their outstanding shares is at $3.3 million. As per the press release, Q2 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.